ANN ARBOR, Mich. – April 1, 2013 – Lycera Corp., a biopharmaceutical company pioneering innovative approaches to developing breakthrough oral medicines to treat autoimmune diseases, today announced the appointment of Laura L. Carter, Ph.D. to vice president, biology.
“I am pleased to welcome Dr. Carter to the Lycera team,” said Kathleen M. Metters, Ph.D., Lycera president and chief executive officer. “Her extensive experience in the inflammation and autoimmune space makes her a key asset to Lycera as we continue to advance our pipeline of first-in-class immunomodulator programs.”
Dr. Carter brings nearly 15 years of scientific experience working in the pharmaceutical industry. Prior to joining Lycera, she was scientific director in the respiratory, inflammation and autoimmunity group at MedImmune, where she was responsible for overseeing research and development of treatments for autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis and multiple sclerosis. Prior to MedImmune, she was a senior research investigator in the inflammation biology and translational science department at Array Biopharma and held scientific positions of increasing responsibility in the departments of inflammation/immunology and cardiovascular/metabolic diseases at Wyeth. Dr. Carter received an S.B. in biological science from Massachusetts Institute of Technology and a Ph.D. in molecular pathology from the University of California, San Diego School of Medicine.
“Lycera is pioneering innovative approaches to developing new medicines for diseases with high unmet medical need,” said Dr. Carter. “I am excited to be joining Lycera’s experienced team of scientists and innovators as the company works to transform the treatment paradigm for patients with autoimmune diseases.”
Lycera Corp. is focused on the discovery and development of selective, small-molecule immune-modulators for the treatment of patients with autoimmune diseases such as rheumatoid arthritis, psoriasis and inflammatory bowel disease. Lycera is developing drug candidates for novel therapeutic targets that have the potential for first-in-class oral efficacy without the adverse effects of current standard-of-care antiproliferative and immunosuppressive agents. Lycera is focused on the emerging areas of cellular bioenergetics and immune-metabolism to selectively target and silence pathologically activated cells. Lycera has a significant research collaboration with Merck for its RORγt program, and in February 2013 expanded its relationship with Merck with a new collaboration agreement to discover, develop and commercialize small-molecule therapies. Lycera’s leadership team and advisors represent the core thought leaders in immunology, inflammation, medicinal chemistry and relevant biology and are responsible for key advances and discoveries in these fields. Visit www.lycera.com for more information.